You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

Duac vs adapalene/BPO (Epiduo)

Go to Close Top

  • DUAC 5%: FASTER ONSET OF ACTION VS ADAPALENE/BPO 1

    • Duac 5% provides significantly greater reductions (median) in inflammatory lesions vs adapalene/BPO at week 4* (p=0.021) 1
    • Time to treatment success** was significantly shorter (p=0.035) for Duac 5% than for adapalene/BPO 1
    Faster onset of action

    The prospective, randomized, invesigator-blind, paraller-group trial, performed in 17 centers in Germany.
    *Reductions were comparable at all other time points.
     1
    **Defined as an improvement of 2 grades or more from baseline on the Investigator's Static Global Assessment (ISGA) scale (a 6-point scale [O=clear skin with no inflammatory lesions; 5=severe acne with many inflammatory and non-inflammatory lesions and more than a few nodular lesions]). 1
    The same results were first published in Zouboulis C, et al. 2009. The graph has been independently created by GSK from the original publication.
    BPO: Benzoyl peroxide.

  • DUAC 5%: FAVOURABLE TOLERABILITY VS ADAPALENE/BPO 1

    • Patients using Duac 5% experienced fewer treatment-related adverse events than patients using adapalene/BP0* (p<0.03) 1
    • Patients using Duac 5% had fewer missed applications during the first 4 weeks of the study due to tolerability issues than those using adapalene/BP0 1

    *Treatment-related adverse events consisted mainly of application site reactions, including dryness, peeling, pruritis and burning/stinging. The same results were first published in Zouboulis C, et al. 2009. The graph has been independently created by GSK from the original publication.
    BPO: Benzoyl peroxide

  • Formulated for once-daily dosing 2

    • Duac is a fixed-dose combination that brings together the benefits of clindamycin and benzoyl peroxide, in an easy-to-use once-daily gel 2
    Easy-to-use once-daily
  • DUAC 5%: COMPARABLE REDUCTIONS IN LESIONS VS ADAPALENE/BP0 1

    • Duac 5% provides comparable mean reductions in inflammatory and non-inflammatory lesions to adapalene/BPO at week 12 1
    Duac efficacy

    *p=0.076 (ns) Duac vs adapalene/BP01; t p=not given. The same results were first published in Zouboulis C, et al. 2009. The graph has been independently created by GSK from the original publication.
    BPO: Benzoyl peroxide

  • DUAC: DUAL-ACTION FORMULA WITH ADDED EMOLLIENTS FOR SKIN MOISTURISATION

    • Clindamycin and BPO work together to produce free radicals which oxidise bacterial proteins and enhance the antibacterial effect of clindamycin 34
    • Duac also contains dimeticone as well as glycerol, 5for added moisturization to mitigate potential irritant effects 6
    Duac dual-action formula

    BPO: Benzoyl peroxide

  • DUAC: HELPS REDUCE THE RISK OF ANTIBIOTIC RESISTANCE 72

    In a pre-specified sub-group analysis study, Duac 5% was shown to: 7

    • Help prevent the development of antibacterial resistant Propionibacterium acnes
    • Reduce the number of strains of existing antibacterial resistant bacteria on the skin
    Anti-microbial resistance

    The same results were first published in Langner A, et al. 2008.
    The graph has been independently created by GSK from the original publication.

  • DUAC: HIGH STRENGTH RECOMMENDATION BY EDF GUIDELINES AS A TREATMENT OPTION FOR MILD TO MODERATE PAPULOPUSTULAR ACNE 8

    • EDF treatment guidelines recommend against the use of topical antibiotics as monotherapy due to the emergence of antibiotic-resistant strains of P. acnes 8
    Treatment guidelines

    BPO: Benzoyl peroxide; EDF: European Dermatology Forum; FDC: Fixed-dose combination

  • DUAC 3%: A LOW-CONCENTRATION BPO OPTION TO MEET DIFFERENT PATIENTS' NEEDS 9

    Duac 3% provides: 10

    • A faster onset of action vs clindamycin 1,2% (p<0.001)
    • Superior reductions in inflammatory lesions vs clindamycin 1,2% (p<0.001) and vs BPO 3% at week 12 (p=0.015)
    • Comparable tolerability with a similar rate of treatment-related adverse events to clindamycin 1,2% and BPO 3%

    *p<0.001 Duac vs clindamycin; b p=0,225 (ns) t p=0.005 Duac vs BP0; r p=0.199 (ns) Duac vs BPO
    The same results were first published in Eichenfield, et al. 2011.
    The graph has been independently created by GSK from the original publication. BPO: Benzoyl peroxide

References:

  1. Zouboulis C, et al. Cutis 2009;84(4 ):223-229.
  2. Duac 5% Summary of Product Characteristics (UK). February 2018.
  3. Burkhart CG, Burkhart CN. Br J Dermatol 2008;159(2):480-481.
  4. Dutil M. Skin Therapy Lett 2010;15(10):5-7.
  5. Dhawan SS. Cutis 2009;83(5):265--272.
  6. Draelos ZD. P/ast Reconstr Surg 2010;125(2):719-724.
  7. Langner A, et al. Br J Dermatol 2008;158(1):122-129.
  8. European Dermatology Forum S3-Guideline for the Treatment of Acne (Update 2016). Available at: http://www.euroderm.org/edf/index.php/edf-guidelines/category/4-guidelines-acne?download=64:guideline-for-the-treatment-of-acne-update-2016 (Last accessed June 2018).
  9. Duac 3% Summary of Product Characteristics (UK). January 2015.
  10. Eichenfield LF, et al. J Drugs Dermatol 2011 ;10(12):1382-1396.

Duac is a registered trademark of the GlaxoSmithKline group of companies.